The majority of patients with chronic obstructive pulmonary disease (COPD) do not receive positive airway pressure (PAP) therapy despite its effectiveness in reducing hospitalizations, according to research.
The majority of patients with chronic obstructive pulmonary disease (COPD) do not receive positive airway pressure (PAP) therapy despite its effectiveness in reducing hospitalizations, according to research.
A new study utilized administrative claims data from the Truven Health MarketScan Database of hospitalizations among patients with COPD who received or did not receive PAP therapy. This includes continuous PAP, bilevel PAP, and noninvasive positive pressure ventilation with a home ventilator.
The study found that 92.5% of 1,881,652 patients with COPD were not using any type of PAP therapy. A minority of the patients received continuous PAP (5.6%), bilevel PAP (1.5%), and noninvasive positive pressure ventilation therapy (<1%). Of the patients who received these treatments, the administrative claims suggest a lower hospitalization risk than before the therapy was initiated compared with those who did not receive any therapy.
“Many clinicians still reference dated information when considering COPD treatment methods, yet technologies, machines, and even masks have advanced significantly since PAP therapy was first introduced,” Eli Diacopoulos, Philips Respiratory Care Business Leader, said in a statement. “This study demonstrates the vast opportunity for the industry to further adopt recent innovations for COPD treatment.”
The research also suggested greater benefits from PAP therapy are associated with comorbidities like sleep apnea, chronic respiratory failure, and heart failure.
“This analysis revealed that there is a solution already accessible within our toolbox that can keep patients out of the hospital, but it is significantly underutilized,” says Sairam Parthasarathy, MD, a professor of medicine and interim chief of Division of Pulmonary, Allergy, Critical Care and Sleep Medicine with University of Arizona College of Medicine. “With improved awareness and implementation of PAP therapy as a treatment for COPD, we can lower the cost burden for health systems while allowing patients to recover in the comfort of their own homes.”
The study acknowledged the need for further research through randomized controlled trials that can establish the causality between PAP therapy and reduced hospitalizations.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More